Last reviewed · How we verify
NCT05528939: FAACTS
Feasibility/Acceptability of Attentional-Control Training in Survivors
NA trial testing EndeavorRx in Pediatric Cancer in 50 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | Children's National Research Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 14 June 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- EndeavorRx
- Control video game
Conditions studied
- Pediatric Cancer — all drugs for Pediatric Cancer →
- Pediatric ALL — all drugs for Pediatric ALL →
- Pediatric Brain Tumor — all drugs for Pediatric Brain Tumor →
- Attention Difficulties — all drugs for Attention Difficulties →
Sponsor
Children's National Research Institute
Who can join
Adults 8 to 16, any sex, with Pediatric Cancer or Pediatric ALL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \> 1 year from the end of therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05528939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of EndeavorRx
Trials testing the same drug.
- NCT05991167 — EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx") · active not recruiting
Other recruiting trials for Pediatric Cancer
Currently open trials in the same condition.
- NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
- NCT07278778 — Cancer Care Companion · NA · recruiting
- NCT07473518 — Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy · recruiting
- NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
- NCT07188311 — Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma · NA · recruiting
Other Children's National Research Institute trials
Trials by the same sponsor.
- NCT07336264 — Characterization of Acute Pain · recruiting
- NCT06938542 — Palliative Care Needs of Children With Rare Diseases and Their Families · NA · enrolling by invitation
- NCT06618027 — Pragmatic Clinic-Based Trial of a Mindfulness Based Intervention for Mood Concerns in Youth With Type 1 Diabetes · NA · recruiting
- NCT06770010 — Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease · NA · recruiting
- NCT06623981 — The Exhale Study: Treating Maternal Depression in an Urban Pediatric Asthma Clinic · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05528939 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's National Research Institute
- Last refreshed: 10 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05528939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing